TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26502272

Group type: EXPERIMENTAL
Intervention: Cold applied immediately after exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Heat applied immediately after exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cold applied 24 hours after exercise
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Heat applied 24 hours after exercise
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 23523986

Group type: EXPERIMENTAL
Intervention: SLI group
Number of subjects: 14

Group type: COMPARATOR
Intervention: TD group
Number of subjects: 14
Study: 21740243

Group type: EXPERIMENTAL
Intervention: Sc+ES+S+V
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sc+ES+EO+V
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sb+AP+PP+CstO
Number of subjects: 96

Group type: COMPARATOR
Intervention: SC+ES+V
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Etch+Sc+ES+S+Us
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sc+ES+S+Fb+V+Fb
Number of subjects: 96
Study: 19128928

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 332
Study: 16362558

Group type: COMPARATOR
Intervention: Conventional pelvic floor muscle exercises
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Digital vaginal control
Number of subjects: 377
Study: 10499079

Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains (ITC)
Number of subjects: 763
Study: 7582282

Group type: EXPERIMENTAL
Intervention: Inhaled wild‐type rhinovirus 16 (RV16) administered at a total dose of 3 x 10(4) TCID50
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo administered in equal doses into both nostrils
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine
Number of subjects: 14
Study: 1782971

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (0.8, 1.6, and 3.2 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral prednisolone (5, 10, and 20 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both inhaled budesonide and oral prednisolone
Number of subjects: 12
Study: 6959170

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31940543

Group type: EXPERIMENTAL
Intervention: GBDT (Gradient Boosting Decision Tree)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2-layer-GA-SVM (Genetic Algorithm-Support Vector Machine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proposed method (fNIRS technology)
Number of subjects: 30
Study: 30472431

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min) applied bilaterally over the prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control (not specified in detail)
Number of subjects: 0
Study: 28183288

Group type: EXPERIMENTAL
Intervention: Physiotherapy (Ph-Tx)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Occlusal splint therapy (Sp-Tx)
Number of subjects: 72
Study: 26764392

Group type: EXPERIMENTAL
Intervention: Integrated care plan using a functional geriatric approach
Number of subjects: 225

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 225
Study: 25095811

Group type: EXPERIMENTAL
Intervention: Two servings of Camembert cheese (2 x 30g) per day for 5 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: Two full-fat yoghurts (2 x 125g) per day for 5 weeks
Number of subjects: 159
Study: 21963104

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride topical gel (OTG)
Number of subjects: 704
Study: 19257867

Group type: EXPERIMENTAL
Intervention: Physical Training (PT) with moderate intensity (50-60% of power achieved during exercise test), 45-60 min duration, 3 times a week.
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group (standard therapy for IHD)
Number of subjects: 392
Study: 17907859

Group type: EXPERIMENTAL
Intervention: telephone‐based continuing care for 12 weeks
Number of subjects: 224

Group type: COMPARATOR
Intervention: group counseling continuing care
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: self‐help involvement during treatment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: self‐efficacy and commitment to abstinence 3 months after treatment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: self‐help beliefs
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: social support
Number of subjects: 224
Study: 14684972

Group type: EXPERIMENTAL
Intervention: AmF toothpaste (1,400 ppm F)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste containing AmF and NaF
Number of subjects: 10

Group type: COMPARATOR
Intervention: NaF toothpaste (500, 1,000 and 1,450 ppm F)
Number of subjects: 10

Group type: COMPARATOR
Intervention: SMFP toothpaste (525, 1,000, 1,450 ppm F)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluoride-free dentifrice
Number of subjects: 10
Study: 9676755

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intramuscularly at 10 AM
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intramuscularly at 6 PM
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison of MTX administration times (10 AM vs 6 PM)
Number of subjects: 23
Study: 7852220

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 300
Study: 29643163

Group type: EXPERIMENTAL
Intervention: Intratracheal Dex (0.5 µg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous Dex (0.5 µg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (Intravenous saline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intratracheal Dex
Number of subjects: 30
Study: 28333551

Group type: EXPERIMENTAL
Intervention: 6-week group program of 2-hour weekly sessions addressing mindfulness of food choices facilitated by a trained dietitian and social worker.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention).
Number of subjects: 30
Study: 25883031

Group type: EXPERIMENTAL
Intervention: Recombinant human soluble thrombomodulin (rhTM) administration
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no rhTM administration)
Number of subjects: 162
Study: 23260769

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Salvianolic acid B (SA‐B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) + Salvianolic acid B (SA‐B)
Number of subjects: 42
Study: 21161250

Group type: EXPERIMENTAL
Intervention: Arthroscopic distal clavicle resection combined with rotator cuff repair (Group 1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Isolated rotator cuff repair (Group 2)
Number of subjects: 83
Study: 20032902

Group type: EXPERIMENTAL
Intervention: Swimming (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Walking (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Conventional Exercise (CE) (Group 3)
Number of subjects: 45
Study: 17199537

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy using non-resorbable expanded polytetrafluoroethylene membranes
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy using bioabsorbable barriers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) therapy
Number of subjects: 31
Study: 15495785

Group type: EXPERIMENTAL
Intervention: In-house coordinator intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (centers without in-house coordinators)
Number of subjects: 8
Study: 11559318

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (160 mg trimethoprim and 800 mg sulfamethoxazole twice daily for 2 weeks, followed by 80 mg trimethoprim and 400 mg sulfamethoxazole twice daily for 5.5 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9692305

Group type: EXPERIMENTAL
Intervention: Topically applied linoleic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8148129

Group type: EXPERIMENTAL
Intervention: System for Augmenting Language (SAL)
Number of subjects: 13
Study: 3169108

Group type: EXPERIMENTAL
Intervention: SR verapamil 240 mg tablets administered every 12 h for 6 consecutive weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered every 12 h for 6 consecutive weeks
Number of subjects: 12
Study: 29422350

Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic (CoC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ceramic-on-polyethylene (CoP)
Number of subjects: 58
Study: 27482958

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 44
Study: 25236582

Group type: EXPERIMENTAL
Intervention: Rehabilitation (resistance and aerobic training, 3 days per week for 12 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 20
Study: 24041351

Group type: EXPERIMENTAL
Intervention: Psoriasis Symptom Diary
Number of subjects: 172
Study: 21439962

Group type: EXPERIMENTAL
Intervention: Enteral nutrition for 30 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Total parenteral nutrition for 30 days
Number of subjects: 78
Study: 19005898

Group type: EXPERIMENTAL
Intervention: Torasemide (5 mg/day) at bedtime
Number of subjects: 113

Group type: COMPARATOR
Intervention: Torasemide (5 mg/day) upon awakening
Number of subjects: 113
Study: 16646353

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Concentric (CON) training
Number of subjects: 38
Study: 12738159

Group type: COMPARATOR
Intervention: Oral misoprostol 600 microg
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 400 microg
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol 600 microg
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Combined rectal groups (400 and 600 microg)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (both doses)
Number of subjects: 295
Study: 10978404

Group type: EXPERIMENTAL
Intervention: Tidal dialysis (TPD)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Continuous cycling PD (CCPD)
Number of subjects: 17
Study: 8797943

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque, 320 mgI/ml)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Iopamidol (Solutrast, 370 mgI/ml)
Number of subjects: 117
Study: 1616156

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 24
Study: 6237623

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg three times a day
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Captopril 37.5 mg twice daily
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg three times a day
Number of subjects: 495

Group type: COMPARATOR
Intervention: Placebo three times a day
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg twice daily
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and Captopril combination
Number of subjects: 495
Study: 31635577

Group type: EXPERIMENTAL
Intervention: Drinking behaviour (≥6 drinks per occasion)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Harmful drinking levels
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to ART
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Binge drinking risk factors
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Binge drinking risk based on beverage type
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Frequency of drinking
Number of subjects: 623
Study: 29447773

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 316

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Aspirin only
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor only
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: No antiplatelet therapy
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Triple therapy (DAPT + oral anticoagulant)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant (OAC) only
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: OAC plus aspirin
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: OAC plus P2Y12 inhibitor
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents without OAC
Number of subjects: 316
Study: 27627785

Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lorcaserin
Number of subjects: 0
Study: 25011657

Group type: EXPERIMENTAL
Intervention: SMS group (received 2 text messages twice a day for 12 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (did not receive any messages)
Number of subjects: 160
Study: 22747980

Group type: EXPERIMENTAL
Intervention: Intramyocardial CD133(+) bone marrow stem cell injection in combination with coronary artery bypass grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 0
Study: 20683172

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 17066227

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 286

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 286
Study: 14992701

Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bilateral calcaneal fractures
Number of subjects: 47
Study: 11546663

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation during and up to 2 h postexercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9565856

Group type: EXPERIMENTAL
Intervention: Two-year cancer course (n=17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 33
Study: 7925204

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (800 micrograms kg‐1 in two divided doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (200 micrograms kg‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (300 micrograms kg‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (500 micrograms kg‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (600 micrograms kg‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (680 micrograms kg‐1)
Number of subjects: 36
Study: 3287970

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 335

Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 335

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 335
Study: 31710635

Group type: EXPERIMENTAL
Intervention: Low-load resistance training (RT30) at 30% of maximal strength (1RM)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-load resistance training (RT80) at 80% of maximal strength (1RM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control session without exercise
Number of subjects: 11
Study: 29992026

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CYP2D6 extensive and intermediate metabolizers
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CYP2D6 poor metabolizers
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Homozygosity of CYP2B6 *5 and *6
Number of subjects: 19
Study: 26795378

Group type: EXPERIMENTAL
Intervention: Parental support programme (6 months duration) including health information for parents, motivational interviewing, and teacher-led activities
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 378
Study: 24366980

Group type: EXPERIMENTAL
Intervention: LBR-101 (any dose)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: LBR-101 (1000 mg or higher)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: LBR-101
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 23199187

Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy (RATE)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Open three-stage transthoracic esophageal resection
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall complications (grade 2 and higher)
Number of subjects: 112
Study: 19207627

Group type: EXPERIMENTAL
Intervention: Supportive coparenting behavior
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Low effortful control with high supportive coparenting behavior
Number of subjects: 92
Study: 17443097

Group type: EXPERIMENTAL
Intervention: Disease Management Programme (DMP)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 173
Study: 15897552

Group type: EXPERIMENTAL
Intervention: AC followed by PTX
Number of subjects: 3060

Group type: COMPARATOR
Intervention: AC
Number of subjects: 3060
Study: 11894615

Group type: EXPERIMENTAL
Intervention: Extended GP information routine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 20
Study: 10102953

Group type: EXPERIMENTAL
Intervention: Budesonide 15 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Budesonide 4.5 mg b.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisolone 20 mg/day
Number of subjects: 24
Study: 7805221

Group type: COMPARATOR
Intervention: Encainide, flecainide, and moricizine at two different dose levels (CAST-I); Moricizine alone at three dose levels (CAST-II).
Number of subjects: 2941

Group type: EXPERIMENTAL
Intervention: Easily suppressed ventricular arrhythmias (after adjusting for other variables).
Number of subjects: 2941
Study: 2319047

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg methylphenidate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 310511

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 100
Study: 30419298

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg PRN
Number of subjects: 500
Study: 27246522

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g of long-chain n-3 polyunsaturated fatty acids)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 533

Group type: COMPARATOR
Intervention: No oil
Number of subjects: 533
Study: 25461496

Group type: EXPERIMENTAL
Intervention: 16-session core weight loss intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: 12-session maintenance component
Number of subjects: 450
Study: 25438678

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (OLAI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 0
Study: 22994863

Group type: EXPERIMENTAL
Intervention: Cypher Select sirolimus-eluting stent (SES)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty (BA)
Number of subjects: 281
Study: 19188561

Group type: EXPERIMENTAL
Intervention: Rigidfix cross‐pin and Intrafix tibial expansion sheath with a tapered expansion screw
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rigidfix femoral and BioScrew interference screw tibial fixation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BioScrew femoral and Intrafix tibial fixation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BioScrew fixation into both tunnels
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 18089984

Group type: EXPERIMENTAL
Intervention: A-CASI (Audio computer-assisted self-interviewing)
Number of subjects: 821
Study: 14985864

Group type: EXPERIMENTAL
Intervention: Standardized uptake value (SUV) images acquired from 30 to 35 min after FMZ administration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Distribution volume (DV) images
Number of subjects: 15
Study: 12271408

Group type: EXPERIMENTAL
Intervention: CHOL PET
Number of subjects: 18
Study: 9613300

Group type: EXPERIMENTAL
Intervention: HemoCue
Number of subjects: 13

Group type: COMPARATOR
Intervention: Coulter Max‐M
Number of subjects: 13

Group type: COMPARATOR
Intervention: HemoCue and Coulter Max‐M
Number of subjects: 13
Study: 7653818

Group type: EXPERIMENTAL
Intervention: Ropivacaine (5 mg/mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine (5 mg/mL)
Number of subjects: 60
Study: 2667156

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg twice daily)
Number of subjects: 95
Study: 314392

Group type: EXPERIMENTAL
Intervention: Fenbufen (500 mg capsules)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (750 mg capsules)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 30572979

Group type: EXPERIMENTAL
Intervention: C-Tb
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: PPD
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: QFT
Number of subjects: 456

Group type: COMPARATOR
Intervention: C-Tb, PPD, QFT
Number of subjects: 456
Study: 27535352

Group type: EXPERIMENTAL
Intervention: 200 μg clonidine orally
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26448622

Group type: EXPERIMENTAL
Intervention: tPA (50 mg Alteplase)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no tPA)
Number of subjects: 24